beta-Lactams without a suicide inhibitor.

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• Existing studies on third-generation cephalosporins and cefepime for extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae infections are limited.
• These studies are retrospective, non-randomized, and often use low dosages lacking pharmacokinetic-pharmacodynamic (PK-PD) correlations.
• Higher clinical failure and mortality rates are observed with ESBL-producing Enterobacteriaceae compared to non-ESBL-producing strains.

Purpose of the Study:

• To evaluate the efficacy of current antibiotic therapies against ESBL-producing Enterobacteriaceae.
• To identify potential alternative treatments for infections caused by these resistant bacteria.
• To highlight the limitations of existing clinical data and suggest future research directions.

Main Methods:

• Review of existing retrospective and non-randomized clinical studies.
• Analysis of treatment outcomes including clinical failure and mortality rates.
• Assessment of antibiotic properties, specifically beta-lactamase stability.

Main Results:

• Third-generation cephalosporins and cefepime show higher rates of clinical failure and mortality in ESBL-producing Enterobacteriaceae infections.
• Current evidence lacks PK-PD correlations with clinical efficacy.
• Temocillin, a beta-lactam stable against ESBLs and AmpC beta-lactamases, is a potential alternative but requires further investigation.

Conclusions:

• Empirical therapy with advanced cephalosporins should be avoided in areas with high prevalence of ESBL-producing Enterobacteriaceae.
• Temocillin warrants consideration for revival due to its stability against key beta-lactamases.
• More robust clinical data are needed to confirm the efficacy and safety of temocillin.